Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

IMA Aseptic Processing Symposium Will Highlight Linde Technology

Linde LLC
Posted on: 13 Sep 16

BRIDGEWATER, N.J., Sept. 12, 2016 /PRNewswire/ -- Linde LLC technology will be highlighted at the upcoming IMA Aseptic Processing Symposium to be held on September 14 and 15 at the Buffalo Marriott Niagara hotel in Amherst, New York. The symposium is designed to explore advances in lyophilization and aseptic processing technology with experts from pharmaceutical and biotechnology companies, scientists and researchers from around the world.

Biologics like proteins, vaccines and other injectables must remain effective from manufacture to patient administration. These substances are expensive, fragile and can lose their efficacy during storage. Lyophilization or dry freezing is a dehydration process for stabilizing these valuable medical substances that is conducted in highly controlled environments and in compliance with strict regulatory guidelines. The temperature at which a vial freezes (ice nucleation temperature) is critical in the process to optimize production times and improve the quality of the final product.

Eugene Wexler, Senior Project Manager at Linde, along with Frank DeMarco, Product Manager, Freeze Drying at IMA Life North America, will be presenting a paper at the symposium, titled: Liquid Nitrogen as a Freeze Drying Cooling Source: Technology and Economic Considerations. Wexler and DeMarco will discuss the advantages of Linde's proprietary CUMULUS® technology, which replaces traditional mechanical cooling system and can be seamlessly integrated into existing lyophilizers, allowing pharmaceutical producers to reach lower temperatures than previously possible.

In addition, Dr. Michael Pikal, Professor and Distinguished Chair in Pharmaceutical Technology at University of Connecticut, will be presenting a paper regarding better control of the freezing process at production scale, highlighting Linde's VERISEQ® Nucleation technology, which controls formation of ice crystals using a sterile cryogenic ice fog resulting in enhanced lyophilization (freeze drying) cycles and improved product uniformity.

Both presentations will take place on Thursday, September 15. Linde will also have an exhibit at the symposium where its cryogenic experts will be available to discuss Linde lyophilization and aseptic processing technology in depth.

About Linde

Linde LLC is a member of The Linde Group, a world leading gases and engineering company. In the 2015 financial year, The Linde Group generated revenue of USD19.7 bn (EUR 17.944 bn), making it one of the leading gases and engineering companies in the world, with approximately 65,000 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.

For more information, see The Linde Group online at

Follow us on our blog: Give it Gas ( 
Twitter: @LindeGases_NA 
Facebook: Linde North America 
LinkedIn: Linde Americas

Editor's Details

Mike Wood

Last updated on: 13/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.